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From models to tools: clinical translation of machine learning
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INTRODUCTION
The past decade has seen a proliferation of neuroimaging-based
machine learning studies in psychosis.1 Furthermore, within the
span of ten years, small local studies with few dozen participants
have evolved into large multi-centre studies with several
hundreds of participants.2–5 In the midst of the search for accurate
models, much attention has been given to methodological
challenges including the impact of sample size,6,7 the limitations
of traditional case–control designs,8,9 how to best deal with
confounding variables10 and the effects of heterogeneity11,12 and
inter-scanner variability,13 just to mention a few. Although there
are still important methodological challenges to overcome,
substantial progress is being made, and a solution to these
challenges is now considered to be a matter of when rather than
if.14,15 Wider discussions in the medical community about the
ethical and legal implications of integrating machine learning
models within diagnostic and prognostic assessment of patients
are also underway.16–20 Taken collectively, the progress being
made towards the development and validation of neuroimaging-
based machine learning models is encouraging, as if the different
pieces of a very complex puzzle were slowly coming together.
Less discussed however, are the challenges related to the
development and validation of machine learning-based clinical
tools. Here the critical distinction is between “models”, which tend
to be developed and validated using a limited number of well
characterised datasets with the aim of maximising accuracy,
sensitivity and specificity, and “tools”, which must be feasible,
acceptable and safe, and provide information that will guide
clinical decision-making in real-world settings. This is a timely
discussion, as a new generation of multi-centre studies aiming to
develop machine learning tools to manage patients with
psychosis is emerging (e.g., PSYSCAN,21 PRONIA—www.pronia.eu).
Let’s imagine that we have developed a neuroimaging-based
machine learning model with high levels of accuracy, sensitivity
and specificity, after addressing the main methodological issues.2
Next we’d like to translate this machine learning model into an
actual clinical tool to support the assessment of individual
patients. What are our main challenges along this translation? In
this opinion piece, we discuss seven critical aspects that require
careful consideration when moving from a “model” to a “tool”.
These include real-world validation, clinical utility, feasibility,
acceptability, safety and finally, dissemination.
Real-world validation
After validating our model using several independent datasets,
collected using different scanners across multiple research sites,
we might feel reassured about its performance in a real-world
setting. Yet our optimism might be premature. This is because
datasets collected for the purpose of research tend to include
patients who meet stringent inclusion/exclusion criteria; unfortu-
nately this highly selected group of patients differ from service
users who do not take part in research (e.g., less severe, lower
comorbidities, less medicated, and higher functioning).22 There-
fore, when it comes to clinical validation, we need to consider not
only the size but also the type of sample. In practice, the validation
of a clinical tool should be done in a naturalist design, where all
service users that may benefit from the tool are approached whilst
having minimal exclusion criteria. It is likely that this will result in
lower accuracies, sensitivities and specificities than the original
validation using research datasets. The silver-lining here is that, if
permitted, the more “naturalistic” data could be used to improve
our tool. Learning from experience is, after all, one of the essential
properties of machine learning.
Clinical utility
Successful validation of our model using real-world data does not
necessarily guarantee clinical utility. For a tool to be clinical useful,
two conditions must be met. First, the tool must provide the
treating clinicians with information which is not already available
to them via conventional clinical assessment. Second, the tool
must provide the treating clinicians with information that will
influence a patient’s clinical management. Based on these
conditions, there are at least four areas of potential clinical utility
in the case of psychosis: (i) prediction of conversion to psychosis in
individuals at clinical high risk (i.e., conversion vs. non-conversion);
(ii) prediction of diagnostic outcome (i.e., affective vs. non-
affective psychosis); (iii) prediction of response to conventional
antipsychotic medication (responders vs. non-responders); and (iv)
prediction of psychotic relapse amongst patients who have
recovered from the acute phase of the illness (relapsers vs. non-
relapsers). In each of these examples, it is not possible to predict
clinical outcome based on the initial clinical presentation
(condition 1), and the prediction has practical implications for
clinical management (condition 2). A critical implication of this
conceptualization of clinical utility is that very high levels of
accuracy, sensitivity and specificity do not necessarily guarantee
clinical utility. For example, a tool developed to distinguish
between patients experiencing psychosis and healthy volunteers
would not add to conventional clinical assessment, and as such
would not be considered clinically useful even in the context of
perfect accuracy, sensitivity and specificity. Conversely, accuracy,
sensitivity, and specificity do not necessarily need to be very high
for a tool to have clinical utility. For example, in circumstances
where the clinical decision represents a “toss-up” and is
subsequently adjusted via trial and error, even a modest
improvement in prediction (e.g., from 50 to 70%) may be
1Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK. ✉email: a.mechelli@kcl.ac.uk
www.nature.com/npjschz
Published in partnership with the Schizophrenia International Research Society
1
2
3
4
5
6
7
8
9
0
()
:,;
considered clinically useful. For completeness it should be
mentioned that tools which do not meet both conditions, but
have the potential of changing the patient’s perceptions and
behaviours around their illness, could also have some clinical
utility. For example, a tool predicting that someone has a very
high chance of benefiting from a certain medication may make
them more tolerant of side effects and less likely to discontinue
treatment.
Feasibility
Next we will need to establish the feasibility of implementing our
tool in a real-world setting. In practice, this would require carrying
out a prospective naturalistic investigation using both quantitative
and qualitative methodologies. Feasibility from the perspective of
healthcare providers could be assessed based on the proportion
of clinical services, which have the capacity to collect the required
neuroimaging data, and have access to the technical infrastructure
to implement the tool. Here potential barriers include absence of
scanning facilities and insufficient computational resources to
process the images in a timely manner. Feasibility from the
perspective of service users could be assessed based on the
proportion of patients who meet the inclusion and exclusion
criteria for our tool, and the proportion of acceptances, refusals
and nonresponses. Here patients with acute psychosis might find
the scanner environment too stressful, thereby limiting the
feasibility of our tool in this phase of the illness. At present, the
feasibility of implementing neuroimaging-based machine learning
tools in clinical services for psychosis is unclear due to the paucity
of empirical data.
Acceptability
Not much is known about the acceptability of machine learning
tools in health care services in what has been recognized as “blind
spot” in AI research.23 Yet such knowledge is particularly
important for mental health applications, where the use of AI
may be perceived as more controversial.24 Negative attitudes
towards AI-based clinical tools amongst clinicians and service
users may pose a significant obstacle to translational implementa-
tion, and as such should be an integral part of any formal
assessment of clinical viability. As part of our prospective
naturalistic study, we would therefore need to measure accept-
ability from the perspectives of clinicians and service users,
covering domains such as helpfulness, ease of use, attractiveness,
safety, and privacy features. In addition, because a questionnaire
might miss potential barriers, we might also want to carry out
face-to-face qualitative interviews with both groups. These inter-
views will provide an opportunity to unearth and understand
concerns about technical aspects (e.g., unreliable internet
connection) as well as operational aspects (e.g., medical staff
being uncomfortable or uncertain about how the output of our
tool can be integrated into clinical assessment).
Safety
A first source of risk in the translational implementation of our tool
relates to the collection of brain scans. While MRI is generally
regarded as a safe procedure, some service users may have
conditions that may pose a risk (e.g., pregnancy). However, the
screening for these conditions and other issues that may affect the
quality of the image is a routine exercise in clinical settings, and as
such should not be a significant barrier. On the other hand,
experiencing stress and anxiety before and/or during the MRI is
not uncommon,25 and services users with acute psychosis may
find the procedure even more challenging.26 A second source of
risk in the translational implementation of our tool relates to the
possible misuse of its output by medical staff. Here the potential
risk is that a clinician will misinterpret and/or misuse the
information with detrimental consequences for the patient. As
part of our prospective naturalistic study, we would therefore
need to measure safety in terms of frequency of adverse events
and inappropriate use of the tool by medical staff.
Dissemination
Having established the clinical utility, feasibility, acceptability, and
safety of our tool using real-world data, we are now ready to make
it available to the wider clinical and research communities. This
raises the question of how to best disseminate our healthcare
innovation. This question requires careful consideration of our aims
and values as healthcare innovators as well as the opportunities
and limitations of the current market. On the one hand, we would
like our tool to improve the way psychosis is diagnosed, monitored
and treated, reducing the burden of the illness on patients, their
carers and the wider society; in order to achieve this aim, it is
imperative that our tool is developed for wide adoption and is
made available to the widest possible cohort of patients. On the
other hand, we need to ensure the long-term sustainability of our
tool in light of its future running costs (e.g., technical updates,
cloud-based hosting, and bug fixing); in order to achieve this aim a
robust plan for market adoption, continuous development, and
financial income generation over a sustained period will be
required. We will therefore need to develop a dissemination and
commercialization plan which combines these aims, covering
aspects such as medical device regulations, unique value proposi-
tion, market size, and revenue streams, data governance and
ethics, cost structure, partnerships, and key risks.27
CONCLUSION
Neuroimaging-based machine learning studies of psychosis are
generating a plethora of academic publications, many of which
are reporting “promising” findings. The ultimate aim of our
research, however, is to find ways of decreasing the burden of this
illness on patients, their carers, and the wider society. In order to
achieve this aim, we need to start translating these machine
learning models into clinical tools. This translation is not
straightforward, as it requires us to move away from the kind of
metrics that are the cornerstone of academic publications (e.g.,
statistical significance of the accuracy) towards measures of
feasibility, acceptability, safety and, of course, clinical utility. A
further stumbling block is that the vast majority of published
studies compared patients with psychosis against healthy
volunteers using a cross-sectional design, and as such produced
findings with little or no clinical utility. In contrast, to develop
machine learning models capable of providing clinically useful
information, we need access to longitudinal data (for example,
whether a patient did or did not respond to a full cycle of
conventional antipsychotic medication). In the near future, a
number of ongoing large-scale studies using a longitudinal design
are expected to come to completion (e.g., PSYSCAN,21 PRONIA—
www.pronia.eu). It is hoped that the data resulting from these
studies will provide our research community with opportunities to
bridge the existing gap between models and tools.
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